09:39 AM EST - Eupraxia Pharmaceuticals Inc. : Announced positive treatment outcomes from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Most notably, nine-month data was disclosed for the first time demonstrating that all three patients dosed at 48mg of EP-104GI experienced sustained or improved treatment outcomes after nine months of therapy. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $5.51.
